Prelude PRLD 深 滬
等待開盤 11-06 09:30:00 美东时间
1.4566
-0.303
-17.24%
華盛通- 最 高1.65
- 今 開1.65
- 成交量 243.15万股
- 最 低 1.43
- 昨 收 1.76
- 總市值 8244.40万
- 52周最高 4.22
- 市盈率 靜 --
- 換手率 4.30%
- 52周最低 0.6101
- 委 比 42.02%
- 總股本 5660.03万
- 歷史最高 95.375
- 量 比 0.22
- 振 幅 12.50%
- 歷史最低 0.6101
- 每 手 1
- 風險率 0.30%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Prelude Therapeutics Signs Option Agreement with Incyte
Prelude Therapeutics ( ($PRLD) ) has provided an update. On November 3, 2025, P...
11-04 22:18
Market-Moving News for November 4th
PRLD: 70% | Prelude Therapeutics Signs Agreement For Incyte To Acquire JAK2V617F JH2 Inhibitor Program In Development For Patients With Myeloproliferative Neoplasms NSP: -32% | Insperity shares are trading
11-04 20:24
美股牛股 | AI军备竞赛持续加码！CIFR大涨超22%，与亚马逊达成数十亿美元交易；艾马克技术涨超17%
AI军备竞赛持续加码！CIFR大涨超22%，与亚马逊达成数十亿美元交易；艾马克技术涨超17%，黄仁勋证实：英伟达携手其生产Blackwell芯片>>
11-04 13:38
Prelude Therapeutics Announces Strategic Business Update
Prelude Therapeutics has entered into an exclusive option agreement with Incyte Corporation for its JAK2V617F mutant selective inhibitor program, involving a $35 million upfront payment, a $25 million equity investment, and potential additional funds if the option is exercised. The company is prioritizing development of its KAT6A selective degrader program for ER+ breast cancer, targeting clinical development in 2026, while pausing its SMARCA2 pr...
11-04 12:05
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting
Prelude Therapeutics announced the presentation of two abstracts at the ASH 67th Annual Meeting highlighting its JAK2V617F mutant selective inhibitors and CALR-targeted degrader antibody conjugates (DACs). The JAK2 inhibitors, which bind to the JH2 "deep pocket" where the V617F mutation resides, showed mutant-specific inhibition in MPN models, with potential for disease modification. The CALR-targeted DACs deliver CDK9 degrader payloads, selectiv...
11-03 14:01
Prelude Therapeutics Appoints Katina Dorton to Board
Prelude Therapeutics ( ($PRLD) ) has provided an update. On October 17, 2025, P...
10-17 19:57
Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors
Prelude Therapeutics announced the appointment of Katina Dorton to its Board of Directors. With over 30 years of experience in healthcare and life sciences, Dorton brings significant leadership and financial expertise. She recently served as Chief Financial Officer at NodThera and previously oversaw finance at Repare Therapeutics, AVROBIO, and Immatics. Dorton also has extensive experience in investment banking with Morgan Stanley and Neuberger B...
10-17 11:30
美股大行评级 | 升至450美元，瑞穗上调特斯拉目标价；富国银行上调CoreWeave至"超配"，目标价升至170美元
今日重点评级关注：Guggenheim：维持MBX Biosciences"买入"评级，目标价从44美元升至84美元；Oppenheimer：维持MBX Biosciences"跑赢大市"评级，目标价从38美元升至80美元
09-24 10:23
HC Wainwright & Co. Reiterates Buy on Prelude Therapeutics, Maintains $5 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $5 price target.
09-23 19:08
